Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309913 | 0.89 | CA4 (0.43) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| SCHEMBL507063 | 0.89 | CA4 (0.43) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL28234445 | 0.87 | POLB (0.42) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| Benzamide SCHEMBL1567388 | 0.85 | PARP10 (0.58) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| Acetic Acid SCHEMBL27465373 | 0.81 | MTNR1A (0.53) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| SCHEMBL9487460 | 0.81 | LTA4H (0.52) | KMT2AMEN1PARP10TSHR | |
| Acetic Acid SCHEMBL27501770 | 0.79 | PARP10 (0.55) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| Citric Acid SCHEMBL3233236 | 0.78 | SLC13A5 (0.48) | MTNR1AMTNR1BCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7651909 | 0.78 | TAAR1 (0.44) | MTNR1AMTNR1BGAAKMT2AMEN1 | |
| SCHEMBL27450538 | 0.78 | GAA (0.55) | MTNR1AMTNR1BGAACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110110913-A1 | PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHODS OF USE THEREOF FOR TREATING CELL DISORDERS | NAD LIFE PTY LTD (AU) | 2011-05-12 | — | — | US | claimed |
| JP-2011513338-A | — | — | 2011-04-28 | — | — | JP | claimed |
| EP-2259782-A1 | PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHODS OF USE THEREOF FOR TREATING CELL DISORDERS | Grant, Ross Stewart (AU) | 2010-12-15 | — | — | EP | claimed |
| WO-2009108999-A1 | PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHODS OF USE THEREOF FOR TREATING CELL DISORDERS | GRANT ROSS STEWART (AU) | 2009-09-11 | — | — | WO | claimed |
| US-10974059-B2 | Treatment of cancer or tumors induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternating magnetic field | NANOBACTERIE (FR) | 2021-04-13 | — | — | US | disclosed |
| US-20200140290-A1 | Remediation of physiologically active compounds from waste water | SECURE NATURAL RESOURCES LLC (US) | 2020-05-07 | — | — | US | disclosed |
| US-20190201704-A1 | TREATMENT OF CANCER OR TUMORS INDUCED BY THE RELEASE OF HEAT GENERATED BY VARIOUS CHAINS OF MAGNETOSOMES EXTRACTED FROM MAGNETOTACTIC BACTERIA AND SUBMITTED TO AN ALTERNATING MAGNETIC FIELD | NANOBACTERIE (FR) | 2019-07-04 | — | — | US | disclosed |
| US-10252073-B2 | Treatment of cancer or tumor induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternating magnetic field | NANOBACTERIE (FR) | 2019-04-09 | — | — | US | disclosed |
| US-10238886-B2 | Treatment of cancer or tumors induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternating magnetic field | NANOBACTERIE (FR) | 2019-03-26 | — | — | US | disclosed |
| US-20170157253-A1 | TREATMENT OF CANCER OR TUMOR INDUCED BY THE RELEASE OF HEAT GENERATED BY VARIOUS CHAINS OF MAGNETOSOMES EXTRACTED FROM MAGNETOTACTIC BACTERIA AND SUBMITTED TO AN ALTERNATING MAGNETIC FIELD | ALPHAONCO (FR) | 2017-06-08 | — | — | US | disclosed |
| US-9512095-B2 | Polymorph forms of desazadesferrithiocin analogs | FERROKIN BIOSCIENCES, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160024034-A1 | POLYMORPH FORMS OF DESAZADESFERRITHIOCIN ANALOGS | FERROKIN BIOSCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20100155330-A1 | TARGET MATERIAL REMOVAL USING RARE EARTH METALS | MOLYCORP MINERALS, LLC (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100137383-A1 | NOVEL SALTS AND POLYMORPHS OF DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | FERROKIN BIOSCIENCES, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010056742-A1 | TARGET MATERIAL REMOVAL USING RARE EARTH METALS | MOLYCORP MINERALS LLC (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2171037-A2 | BIOREACTOR | Algaedyne Corportion (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010009120-A2 | NOVEL SALTS AND POLYMORPHS OF DESAZADESFERRITHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | FERROKIN BIOSCIENCES, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009108999-A1 | PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHODS OF USE THEREOF FOR TREATING CELL DISORDERS | GRANT ROSS STEWART (AU) | 2009-09-11 | — | — | WO | disclosed |
| US-20090013742-A1 | COMPOSITIONS AND METHODS FOR WASTEWATER TREATMENT | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2009002772-A2 | BIOREACTOR | ALGAEDYNE CORPORTION (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110913-A1 | PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHODS OF USE THEREOF FOR TREATING CELL DISORDERS | SIRT1, SIRT2, SIRT6 | MTNR1A 799/4885MTNR1B 1187/4885GAA 967/4885 |
| US-20100137383-A1 | NOVEL SALTS AND POLYMORPHS OF DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | SLC39A14, SLC40A1, SLC39A11 | MTNR1A 2772/4885MTNR1B 3349/4885GAA 635/4885 |
| US-20160024034-A1 | POLYMORPH FORMS OF DESAZADESFERRITHIOCIN ANALOGS | SLC39A14, FTH1, SLC40A1 | MTNR1A 2650/4885MTNR1B 2454/4885GAA 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.